All News

RheumNow Podcast square

Two Week Twitter (6.17.2022)

d Jack Cush, MD

Dr. Jack Cush does a 2-week review of RheumNow Tweets on news and journal citations worth noting, along with some opinions on Telehealth, manpower, monkeypox and the price of drugs.

Read Article
Distance

PsA UPLIFT survey: do rheumatologists and patients agree on treatment goals?

d Rachel Tate, DO

POS0309 at EULAR 2022 highlighted both similarities and differences between our patients and ourselves when it comes to PsA disease and treatment strategies. 

Read Article
Biologic.choice.MD_.jpeg (keep)

Not All RA Drug Classes Are Created Equal

d MedPage Today

Clear differences were apparent among the three major types of targeted medications for rheumatoid arthritis (RA) in a large European registry study.

Read Article
JAK Janus

JAK/STAT pathway in pyoderma gangrenosum: a new therapeutic highway?

d Aurelie Najm, MD, PhD

Pyoderma gangrenosum (PG) is rare, but often associated with different forms of arthritis, in particular rheumatoid arthritis and inflammatory bowel diseases. 

Read Article
Vaccination,vaccine

Flares Not Increased Following Recombinant Zoster Vaccine Injections

d Jack Cush, MD

Insurance claims analysis has shown that the use of the (CDC recommended) recombinant zoster vaccine (RZV) for prevention of herpes zoster was highly used in patients with immune-mediated inflammatory diseases and was safe, as higher rates of arthritis flares were not evident.

Read Article
covid coronavirus virus

Spondyloarthritis and COVID-19

d Robert Chao, MD

There are still questions surrounding COVID-19, and some common questions I receive from patients revolve around what to do with their current DMARDs or should they even start treatment during this pandemic. Two studies focused on this question. 

Read Article
Watch: Dr. Lucy Carter on RNA-Seq analysis to determine who's at risk for SLE Dr. Yusof interviews Dr. Lucy Carter ( @LucyCarter6), winner of the #EULAR2022 Best Abstract Award for her work on ANA positivity in those at-risk for progression to #SLE. https://t.co/BdPnZRgwX4 https://t.co/g8xWWFthVC

Links:

Dr. John Cush RheumNow ( View Tweet)
COVID-19 hospitalization among Medicare diabled was ~50% higher (3,148/100k) than age matched pop. , and hospitalization rates increased with age in both groups. Among the disabled, American Indian or Alaska Natives had highest rate https://t.co/Xa4NlalHdf https://t.co/dP0c3ajQAW

Links:

Dr. John Cush RheumNow ( View Tweet)
Although Rheumatology currently ranks 2nd or 3rd in specialty use of telemedicine - the vast majority of rheums have given up on telehealth (<15%) https://t.co/iDNesBkOnN
Dr. John Cush RheumNow ( View Tweet)
Australian Bureau of Statistics 2017–2018 shows relative risk of undergoing knee replacement for OA increased with increasing BMI (Class 1- 3 obese females 55–64 yrs had 4.7 to 17.3 fold risk of KR. Same for obese Males (OR 3.4 - 5.8) more KR https://t.co/vcPmRgbzUH https://t.co/FrfTC9LNnR

Links:

Dr. John Cush RheumNow ( View Tweet)
31 systemic JIA pts: w/ systemic sxs (n=8), chronic arthritis (7), remission on meds (10) & remission off meds (6). High IL-18 levels & impaired IL-18 signaling in NK cells correlated with systemic Dz activity. High IL-18 impairs NK phosphorylation https://t.co/HlaQid7xGq https://t.co/0PbxC0pZtk

Links:

Dr. John Cush RheumNow ( View Tweet)
Lit search on (Lyme) Borrelia burgdorferi sensu lato shows global Bb seroprevalence =14.5% (top 3: Central Europe 20.7%,Eastern Asia 15.9%, Western Europe 13.5%). Bb seropositivity assoc w/ ≥50 yrs, men & residence of rural area https://t.co/fvr845s5CC https://t.co/TLNumNuXnH

Links:

Dr. John Cush RheumNow ( View Tweet)
Balance and falls studied in 228 #RA pts (24-85 yrs) followed x 1yr; 20% had at least one fall; risks included Age (OR 1.04), HAQ (OR 1.62), low FICSIT-4 score (OR 2.38) & 1-leg standing (OR  2.14). 1-leg stand is a good screening tool https://t.co/u9v8unC0gA https://t.co/oD0sgFxiQm

Links:

Dr. John Cush RheumNow ( View Tweet)
Small study 34 biologic-naive RA pts starting abatacept. Remission achieved 47.1% of early and 23.5% established RA. Remission @ 6 mos predicted by Baseline LOWER IL-6 levels ≤ 8.4 pg/ml, (66.7%) and CD4+CD25+FoxP3+ cells ≥ 6% (83.3%) https://t.co/N93E9M4M15

Links:

Dr. John Cush RheumNow ( View Tweet)

There are 494K PCPs in the USA, While up to 1/3 will "refill" DMARDs, only 6-9% are confident or knowledgeable in "initiating" DMARD therapy in #RA. GIGANTIC NEED FOR PCP education in MSK & Rheum Dz https://t.co/VjgWWDt3nX https://t.co/dTRXxsrzG5

Links:

Dr. John Cush RheumNow ( View Tweet)

OA Initiative Study of 1212 knee OA pts (age 63 yrs), 73% walked for exercise. Walkers had signif. less New frequent knee pain (OR 0.6) & medial joint space narrowing (OR 0.8). Walking for exercise should be encouraged in knee OA pts. https://t.co/MLs9zutdRd

Links:

Dr. John Cush RheumNow ( View Tweet)

Watch: Fatigue and Central Sensitization in Rheumatic Disease - We're sharing Philip Mease, MD presentation from the RheumNow Live 2022 meeting held in March. https://t.co/SFzsszL1aM https://t.co/DkxVPim9iU

Links:

Dr. John Cush RheumNow ( View Tweet)
Learn how clinical research targeting immune pathways can help reduce the burden of #psoriaticarthritis symptoms, such as joint pain, stiffness, and swelling, as well as fatigue: https://t.co/ReBQVyYVka Sponsored by Janssen @JanssenUS https://t.co/fRb6kAj848

Links:

Dr. John Cush RheumNow ( View Tweet)
Study of interferon (IFN) gene signature (IGS) finds IGS elevated in half of early RA pts; high IGS portends higher DAS28, fewer EULAR good resp & higher IFN-α; the latter assoc w/ epigentic changes, more lymphoctye activation. IFN-α as a biomarker? https://t.co/BHC98OR30A https://t.co/SRE7KVaoha

Links:

Dr. John Cush RheumNow ( View Tweet)
Yesterday the FDA approved baricitinib (Olumiant) as the first systemic treatment for Alopecia Areata. Approval based on 2 DBRPCT Trial AA-1, AA-2) - 32% & 35% of pts on Bari 4 mg regrew scalp hair coverage by wk 36. https://t.co/SU74OxI2BC https://t.co/2wluug1fj4

Links:

Dr. John Cush RheumNow ( View Tweet)
×